J-Code Trade Name Drug Name Required Medical Information
|
|
- Ruby Willis
- 6 years ago
- Views:
Transcription
1 FIDELIS CARE NEW YORK DEPARTMENT OF PHARMACY SERVICES Updated: 10/31/2017 J-Code Prior Authorizations & Required Clinical Information Medicaid, Child Health Plus, HealthierLife, Metal-Level J-Code Trade Name Drug Name Required Medical Information J0129 Orencia Abatacept, tuberculin skin test results or quantiferon gold lab results within 12 months, immunization history J0135 Humira Adalimumab, tuberculin skin test results or quantiferon gold lab results within 12 months, immunization history J0180 Fabrazyme Algalsidase beta Enzyme assay showing deficiency of alpha-galactosidase activity or DNA testing Copies of lab results e.g. IgG, IgE J0205 Ceredase Alglucerase Copies of lab results e.g. CBC, platelets, liver function tests, plasma glucocerebroside, IgG antibody J0215 Amevive Alefacept Copies of lab results e.g. CD4 + T-lymphocyte, transaminase Immunization history, body surface area affected, tuberculin skin test results or quantiferon gold lab results within 12 months History of phototherapy trial if applicable J0220 Myozyme Alglucosidase alfa e.g. IgG & IgE antibodies J0221 Lumizyme Alglucosidase alfa e.g. IgG & IgE antibodies 1
2 J0256 Prolastin-C Aralast-NP Zemaira Alpha 1-proteinase inhibitor, FEV 1, pulmonary function tests, smoker status e.g. AAT levels or genetic testing confirming AAT deficiency J0257 Glassia Alpha 1-proteinase inhibitor, FEV 1, pulmonary function tests, Hepatitis B status, smoker status e.g. AAT levels or genetic testing confirming AAT deficiency J0270 Caverject Alprostadil injection Appropriate clinical documentation per indication J0275 Muse Alprostadil urethral suppository Appropriate clinical documentation per indication J0476 Lioresal Baclofen intrathecal J0480 Simulect Basiliximab Planned immunosuppressive regimen containing tacrolimus, belatacept, sirolimus, or cyclosporine e.g. CBC with differential J0490 Benlysta Belimumab, immunization history Previous medication history with trial dates and outcomes J0570 Probuphine Buprenorphine implant J0571 Buprenorphine J0572 J0573 J0574 J0575 Buprenorphine/ naloxone 2
3 J0585 Botox Onabotulinum toxina J0586 Dysport Abobotulinum toxina J0587 Myobloc Rimabotulinum toxinb J0588 Xeomin Incobotulinum toxin A J0592 Buprenex Buprenorphine J0597 Berinert C1-esterase inhibitor 12 years of age J0598 Cinryze C1-esterase Inhibitor 9 years of age J0638 Ilaris Canakinumab, immunization history Copies of lab results e.g. CRP and amyloid A levels, CBC with differential, tuberculin skin test results or quantiferon gold lab results within 12 months J0706 Cafcit Caffeine citrate, serum caffeine levels Gestational age J0717 Cimzia Certolizumab pegol, tuberculin skin test results or quantiferon gold lab results within 12 months, immunization history J0725 Novarel, Pregnyl (Multiple) Chorionic gonadotropin e.g. serum fasting testosterone levels, FSH & LH level 3
4 J0775 Xiaflex Clostridium histolyticum J0897 Prolia Xgeva Denosumab Documentation of involvement of metacarpophalangeal or proximal interphalangeal joints Positive table top test including concurrent calcium and vitamin D intake including fracture history Copies of pertinent lab results e.g. bone mineral density (T score) J1050 Depo-Provera Medroxyprogesterone Appropriate clinical documentation per indication J1071 Testosterone cypionate e.g. sting level of serum total testosterone collected by 10am J1290 Kalbitor Ecallantide 16 years of age J1300 Soliris Eculizumab Meningococcal vaccine at least 2 weeks prior to treatment, immunization history, Copies of lab results e.g. CBC with differential, lactic dehydrogenase (LDH), serum creatinine J1322 Vimizim Elosulfase alfa 5 years of age Documented patient height & weight J1325 Flolan Epoprostenol, right heart cauterization history, baseline 6 minute walking distance test WHO Group, NYHA Class 4
5 J1438 Enbrel Etanercept Patient weight, tuberculin skin test results or quantiferon gold lab results within 12 months, hepatitis B screening J1459 J1556 J1559 J1561 J1566 J1569 J1599 J1460 J1557 J1560 J1562 J1568 J1572 Privigen, Gammagard Gammaplex Carimune (Multiple brand names) IV immune Globulin Documented ideal body weight, actual body weight, immunization history e.g. serum creatinine/bun, platelets, Ig levels Absence of risk factors for acute renal failure and IgA deficiency Documentation of the severity of the condition, including frequency and severity of infections when applicable Documentation of diagnostic evidence supporting the indication for which immune globulin is requested demonstrating the member meets criteria for the disease specific guidelines for use, if available J1595 Copaxone Glatiramer acetate Documentation of diagnostic evidence supporting the indication for which glatiamer acetate is requested e.g. MRI results J1740 Boniva Ibandronate including concurrent calcium and vitamin D intake including fracture history e.g. bone mineral density (T score) J1742 Corvert Ibutilide fumarate J1743 Elaprase Idursulfase Enzyme assay demonstrating a deficiency of iduronate 2-sulfatase enzyme activity or DNA testing J1745 Remicade Infliximab, tuberculin skin test results or quantiferon gold lab results within 12 months, hepatitis B status History of present disease state and progression in medical records 5
6 J1786 Cerezyme Imiglucerase Documentation of diagnostic evidence supporting the indication for which it is requested e.g. CBC, platelets, hemoglobin, hematocrit, liver function tests, IgG antibody, acid phosphatase, MRI/CT results of liver and spleen β-glucocerebrosidase enzyme assay, DNA testing, or bone marrow histology confirming diagnosis J1826 Avonex Interferon beta-1a Documentation of diagnostic evidence supporting the indication for which interferon is requested e.g. MRI results J1830 Betaseron Extavia Interferon beta-1b Documentation of diagnostic evidence supporting the indication for which interferon is requested e.g. MRI results J1930 Somatuline Lanreotide e.g. serum GH, IGF-1, glucose levels, heat rate, gall bladder ultrasonography, TRH tests, CT results of pituitary Previous history of surgery and/or radiotherapy J1931 Aldurazyme Laronidase, alpha-l iduronidase activity or DNA testing confirming diagnosis Previous medication history with trial dates and outcomes J2020 Zyvox Linezolid Copies of lab results e.g. culture, antibiotic sensitivity results, CBC with differential J2170 Increlex Mecasermin 2 years of age Documented patient height and weight J2182 Nucala Mepolizumab 12 years of age Documented patient height, weight, FEV1 % (without bronchodilator) e.g. IgE levels 6
7 J2323 Tysabri Natalizumab Copies of pertinent diagnostic tests e.g. MRI results J2357 Xolair Omalizumab e.g. IgE levels, positive allergy tests, pulmonary function tests, smoking status e.g. number of asthma exacerbations, ER visits, significant functional impairment Age 12 years of age J2358 Zyprexa Relprevv Olanzapine J2426 Invega Sustenna Paliperidone J2440 Papacon Papaverine J2503 Macugen Pegaptanib Intraocular pressure, baseline visual acuity J2507 Krystexxa Pegloticase e.g. serum uric acid level, G6PD deficiency screening e.g. number of gout attacks, gout tophus or gouty arthritis J2562 Mozobil Plerixafor e.g. serum creatinine, CBC with differential, platelets J2778 Lucentis Ranibizumab Intraocular pressure, baseline visual acuity 18 years of age J2786 Cinqair Reslizumab Documented patient height, weight, FEV1 % (without bronchodilator) e.g. IgE levels 7
8 J2793 Arcalyst Rilonacept, immunization history, tuberculin skin test results or quantiferon gold lab results within 12 months e.g. lipid profile, CBC with differential, C-reactive protein, serum amyloid A 12 years of age J2794 Risperdal Consta Risperidone J2796 Nplate Romiplostim e.g. CBC with differential, platelets J2840 Kanuma Sebelipase alfa 1 month of age and height Copies of lab results e.g. liver function and lipase levels Documentation of diagnostic evidence supporting the indication for which drug is requested J3121 J3145 Testosterone enanthate Testosterone undecanoate e.g. fasting level of serum total testosterone collected by 10am e.g. fasting level of serum total testosterone collected by 10am J3262 Actemra Tocilizumab, immunization history, hepatitis B status e.g. CBC with differential, liver function tests, lipid panel, tuberculin skin test results or quantiferon gold lab results within 12 months J3285 Remodulin Treprostinil, right heart cauterization history, baseline 6 minute walking distance test WHO Group, NYHA Class J3355 Bravelle Urofollitropin Appropriate clinical documentation per indication 8
9 J3357 Stelara Ustekinumab, tuberculin skin test results or quantiferon gold lab results within 12 months, immunization history, body surface area affected History of phototherapy trial if applicable J3385 VPRIV Velaglucerase alfa e.g. CBC, platelets, hemoglobin, hematocrit, liver function tests, IgG antibody, acid phosphatase, MRI/CT results of liver and spleen, evidence of bone disease (DEXA scan) J3396 Visudyne Verteporfin e.g. CBC with differential, liver function tests, fluorescein angiography Baseline visual acuity J3489 Reclast Zoledronic acid J3490 J3590 Unclassified drugs; Unclassified biologics Appropriate clinical documentation per indication J7175 Coagadex factor X (human) J7178 RiaSTAP human fibrinogen concentrate J7179 Vonvendi Von Willebrand factor (recombinant) J7180 Corifact Factor XIII (human) J7181 Tretten factor XIII A-subunit (recombinant) 9
10 J7182 Novoeight factor VIII (recombinant) J7183 J7184 J7186 J7187 J7185 J7188 Wilate Humate P Xyntha Von Willebrand Factor Complex, human Factor VIII, recombinant J7189 Novoseven Factor VIIa, recombinant J7190 Koate Factor VIII, human J7191 J7192 J7193 Helixate FS (Multiple) Alphanine, Mononine Factor VIII, recombinant Factor IX, nonrecombinant J7194 J7195 J7196 Bebulin VH (Multiple) Factor IX, complex Benefix Factor IX recombinant Copies of pertinent lab results 10
11 J7198 J7199 Feiba VH (Multiple) Anti-inhibitor coagulant complex Hemophilia clot factor NOC J7200 Rixubis Injection, factor IX, (antihemophilic factor, recombinant) J7201 Alprolix factor IX, Fc fusion protein, (recombinant) J7202 Idelvion factor IX, albumin fusion protein, (recombinant) J7205 Eloctate factor VIII, Fc fusion protein (recombinant) J7207 Adynovate factor VIII, (antihemophilic factor, recombinant), pegylated J7209 Nuwiq factor VIII, (antihemophilic factor, recombinant) J7297 Liletta Levonorgestrelreleasing intrauterine contraceptive system J7298 Mirena Levonorgestrelreleasing intrauterine contraceptive system Copies of pertinent lab results Appropriate clinical documentation for indication Appropriate clinical documentation for indication 11
12 J7300 ParaGard Intrauterine copper Appropriate clinical documentation for indication contraceptive J7301 Skyla Levonorgestrelreleasing Appropriate clinical documentation for indication intrauterine contraceptive system J7303 Nuvaring Ethinyl Estradiol and Appropriate clinical documentation for indication Etonogestrel ring J7304 Xulane Ethinyl Estradiol and Appropriate clinical documentation for indication Norelgestromin patch J7306 Levonorgestrel implant Appropriate clinical documentation for indication system J7307 Imaplanon Etonogestrel implant Appropriate clinical documentation per indication Nexplanon system J7308 Levulan kerastick Aminolevulinic acid HCl Appropriate clinical documentation per indication Previous medication history trial dates and outcomes J7309 Methyl aminolevulinate Appropriate clinical documentation per indication Previous medication history trial dates and outcomes J7312 Ozurdex Dexamethasone Intraocular pressure, baseline visual acuity J7320 J7322 J7324 J7326 J7328 J7321 J7323 J7325 J7327 Synvisc Genvisc Orthovisc Euflexxa (Multiple) Hyaluronan or derivative Physical therapy J73365 Qutenza Capsaicin J7342 Otiprio Ciprofloxacin otic J7511 Thymoglobulin Antithymocyte globulin Planned immunosuppressive regimen containing tacrolimus, belatacept, cyclosporine, or Rapamune e.g. CBC with differential, platelet count 12
13 J7515 Sandimmune Gengraf Neoral Cyclosporine Transplant status if applicable J7516 Sandimmune Cyclosporine Transplant status if applicable J7517 CellCept Mycophenolate mofetil Documentation of negative pregnancy status for woman of child bearing potential Transplant status if applicable J7518 Myfortic Mycophenolate Documentation of negative pregnancy status for woman of child bearing potential Transplant status if applicable J7520 Rapamune Sirolimus No major surgeries within 6 weeks of start date Transplant status if applicable J7525 Prograf Tacrolimus Transplant status if applicable J7527 Afinitor Everolimus No major surgeries within 6 weeks of start date Transplant status if applicable J7599 Immunosuppressive drug not otherwise classified Appropriate clinical documentation per indication J7607 Levalbuterol comp J7609 J7610 Albuterol comp 13
14 J7622 Beclomethasone inhalation comp J7624 J7626 J7629 J7633 J7634 J7635 J7636 J7637 J7638 Betamethasone inhalation comp Budesonide inhalation UD Bitolterol inhalation comp Budesonide inhalation Atropine inhalation comp Dexamethasone inhalation comp J7639 Pulmozyme Dornase alfa Pulmonary function tests 3months of age J7641 Flunisolide inhalation comp J7642 J7643 J7659 J7680 J7681 J7683 J7684 Glycopyrrolate inhalation comp Isoproterenol HCl inhalation UD Terbutaline inhalation comp Triamcinolone inhalation comp J7685 Tobramycin comp 14
15 J7686 Tyvaso Treprostinil inhalation, right heart cauterization history, baseline 6 minute walking distance test WHO Group, NYHA Class J8510 Myleran Busulfan e.g. CBC with differential, platelet count, liver function tests J8515 Cabergoline J8520 J8521 Xeloda Capecitabine Appropriate clinical documentation for indication J8560 Etoposide Appropriate clinical documentation for indication J8597 Antiemetic drug Appropriate clinical documentation per indication J8600 Melphalan J8650 Nabilone Appropriate clinical documentation for indication J8700 Temodar Temozolomide, height, Copies of lab results e.g. CBC with differential, platelet count, liver function tests History of present disease state and progression in medical records J8999 Prescription drug, oral, chemotherapy Appropriate clinical documentation for indication J9228 Yervoy Ipilimumab Documented patient weigh e.g. liver function tests J9302 Arzerra Ofatumumab, Hepatitis B status Copies pertinent lab results e.g. CBC with differential, platelet count J9310 Rituxan Rituximab, height, Hepatitis B status e.g. CBC with differential, platelet count ***Fidelis Care mandates the use of generic drugs, if available*** 15
RAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC)
INFECTIOUS DISEASE ACTIMMUNE INTERFERON GAMMA 1B J9216 ADVATE RAHF PFM ONCOLOGY ORAL AFINITOR EVEROLIMUS J7527 INFECTIOUS DISEASE ALFERON N INTERFERON ALFA N3 J9215 ALPHANATE VWF J7186 ALPHANINE SD J7193
More informationBCBS AZ ADV PLUS * CLASSIC * PREMIER For use with members associated with the BHN Network Prior Authorization List 2015
Prior Authorization List 2015 Participating providers are responsible to furnish or arrange health care services with other participating healthcare facilities or providers. Prior authorization requests
More informationMedStar Medicare Choice Pharmacy Services
Pharmacy Services 1 MedStar Medicare Choice Pharmacy Services Table of Contents At a Glance..page 2 Pharmacy Policies..page 4 Medicare Choice Pharmacy Programs..page 6 Where to Obtain Prescriptions..page
More informationFIDELIS CARE NEW YORK DEPARTMENT OF PHARMACY SERVICES J Code Prior Authorizations & Required Clinical Information 2011 (Updated 3/14/11)
FIDELIS CARE NEW YORK DEPARTMENT OF PHARMACY SERVICES J Code Prior Authorizations & Required Clinical Information 2011 (Updated 3/14/11) Brand Generic J Code Covered Uses Required Medical Information and
More informationSPECIALTY PHARMACY Master Clinical Drug List
Abraxane J9264 Provider ONCOLOGY None NO Actemra J3262 Provider ARTHRITIS PA - all YES Acthar HP Gel J0800 Prov/Self Med/Pharm ENDOCRINE/METABOLIC PA - all YES Adagen J2504 Provider ENZYME DISORDERS None
More informationDrug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015
J0129 Injection, abatacept (Orencia ), 10 J0178 Injection, aflibercept (Eylea ), 1 J0256 J0257 J0585 J0586 J0587 J0588 J0597 J0641 J0717 J0800 Injection, alpha 1-proteinase inhibitor, human (Aralast NP,
More informationProvider Administered Drug Program (PADP) and Physician Administered Drug VPSS List
Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List Code Drug Name Effective and/or Term Date J0129 Injection, abatacept (Orencia ), 10 mg J0178 Injection, aflibercept (Eylea
More informationMDwise Self-Administered Codes for Medical
The following codes are associated with medications that can be self-administered by the patient or a caregiver. As a result, MDwise will transfer coverage of these self-administered medications exclusively
More informationAetna Better Health. Specialty Drug Program
Aetna Better Health is managed through CVS Health Specialty Pharmacy. The Specialty pharmacies fill prescriptions and ship drugs for complex medical conditions, including multiple sclerosis, rheumatoid
More informationInjections Requiring Prior Authorization
At VIVA Health, we strive to keep our provider network informed of any changes. Most of you may currently obtain prior authorizations for administered injections. Below is a list of injection, infusion,
More informationBCN Advantage SM requirements for drugs covered under the medical benefit
J0586 ABOBOTULINUMTOXINA Dysport X X X the medication is being used to treat J0178 AFLIBERCEPT Eylea X X X X X of Neovascular (Wet) -Related Macular Degeneration of Macular Edema following either central
More informationPA Category Name Code(s) Additional Notes ABA 0364T 0365T 0366T 0367T 0373T 0374T H G0396. Applied Behavioral Analysis stage 3*
ABA BEHAVIORAL HEALTH CHEMICAL DEPENDENCY Applied Behavioral Analysis stage 3* Neuropsychological Testing Chemical Dependency/Substance Abuse* (MA Only) 0364T 0365T 0366T 0367T 0373T 0374T H2020 96116
More informationPharmacy and Medical Guideline Updates
STAT Bulletin PO Box 15013 Albany, New York 12212 August 2, 2010 Volume 8: Issue 19 To: All PCPs and Specialists Contracts Affected: All Lines of Business Pharmacy and ical Guideline Updates As a result
More informationList of Designated High-Cost Drugs
List of Designated High-Cost Drugs UPDATED APRIL 25, 2018 For details on the High-Cost Drug policy, see Section 5.8 of the PharmaCare Policy Manual. Recent updates appear in red. Deletions are listed at
More informationPharmacy Services Request Types
FOR DRUG REQUESTS, ONLY-- * NOTE: Only those drugs administered by a healthcare provider and billed medically would be entered via CareAffiliate. * Oral drugs would not be administered by a healthcare
More information2016 MDwise HIP Medical Services that Require Prior Authorization
2016 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services Facility to facility ambulance
More informationPRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION
Abstral fentanyl citrate oral tablet Controlled Dangerous substance Actemra tocilizumab Monoclonal antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate
More informationVivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19
Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19 All Non-Par Provider Requests Requires Authorization Regardless of Service J0178 J0180 J0202 J0205
More information1199SEIU Benefit Funds
1199SEIU Benefit Funds MEDICAL BENEFIT MANAGEMENT PROGRAM SPECIALTY DRUG LIST Effective October 1, 2016 As of April 1, 2015, providers must use the web-based Expressth platform to obtain prior authorization
More informationPA Category Name Code(s) Additional Notes ABA. Applied Behavioral Analysis stage 3*
ABA BEHAVIORAL HEALTH CHEMICAL DEPENDENCY Applied Behavioral Analysis stage 3* Neuropsychological Testing Chemical Dependency/Substance Abuse* (MA Only) 0373T H2020 96116 96112 96113 96121 96130 96131
More informationThe following are J Code requirements
The following are J Code requirements J Codes 20610 Arthrocentesis, aspiration and/or injection; major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa) A9579 Injection, gadolinium based
More information1199SEIU Benefit Funds
1199SEIU Benefit Funds MEDICAL BENEFIT MANAGEMENT PROGRAM SPECIALTY DRUG LIST Effective April 1, 2017 As of April 1, 2015, providers must use the web-based Expressth platform to obtain prior authorization
More informationMedication Prior Authorization Form
Section I Member Information Name (Last, First, Middle Initial) Date of Birth WEA Trust Subscriber Number Diagnosis Page 2 1. MEDICATION 2. STRENGTH 3. DIRECTIONS 4. QUANTITY FEIBA NF NovoSeven RT HEMOFIL
More information2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization
2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services
More information2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization
2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services
More information2016 MDwise HIP Medical Services that Require Prior Authorization
2016 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Coding All Out of Network services Facility to facility ambulance transport
More informationOriginal Policy Date
MP 5.01.17 Specialty Drugs Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/ Date Local policy Last updated/12:2013 Return to Medical Policy Index
More informationMDwise Hoosier Care Connect Medical Services that Require Prior Authorization
MDwise Hoosier Care Connect Medical Services that Require Prior Authorization Certain Indiana Health Coverage Programs (IHCP) services require prior authorization (PA) for members enrolled in the Hoosier
More informationMedication Policy Manual. Policy No: dru408. Topic: Site of Care Review Date of Origin: July 10, 2015
Medication Policy Manual Policy No: dru408 Topic: Site of Care Review Date of Origin: July 10, 2015 Committee Approval Date: August 17, 2018 Next Review Date: August 2019 Effective Date: October 1, 2018
More information1199SEIU Benefit Funds
1199SEIU Benefit Funds MEDICAL BENEFIT MANAGEMENT PROGRAM SPECIALTY DRUG LIST Effective October 1, 2017 As of April 1, 2015, providers must use the web-based ExpressPAth platform to obtain prior authorization
More informationPrior treatment with non-biologic Disease- Modifying Antirheumatic. Not to be used in combination with another biologic DMARD
Abatacept (Orencia) 1, 2, 7, 11, 13, 14, 18, 24, 31, 44, 48, 49, 51, 53, 55, 57 J0129 Alpha 1 - Proteinase inhibitor (Prolastin-C) 5, 6, 10, 12, 40 Medically Necessary (if all the following criteria apply):
More informationPrior Authorization Program
Prescription Drug List January 2011 Prior Authorization Program The prior authorization program helps us offer broad prescription drug coverage and promotes safe, clinically appropriate drug usage. Under
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Clotting Factors and Antithrombin Effective Date... 4/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 8007 Table of Contents Coverage Policy...
More informationMETABOLIC, IMMUNE DISORDERS OR INHERITED RARE DISEASE ALPHA-1 PROTEINASE INHIBITORS ARANESP BLOOD CELL DEFICIENCY ARANESP ARCALYST
PRIOR AUTHORIZATION LIST (SUBJECT TO CHANGE) MEDICATION THERAPEUTIC CATEGORY MODULE ACTEMRA INFLAMMATORY CONDITIONS ACTEMRA ADCIRCA PULMONARY HYPERTENSION PDE-5 INHIBITORS FOR PAH ADDYI SEXUAL DISORDERS
More informationSTAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business
STAT Bulletin November 28, 2011 Volume 9: Issue 27 To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat
More informationINJECTABLE MEDICINES. Resources, Links or Additional Information. J Code Brand Names Generic names Prior Authorization or Restrictions
J9190 5-FU fluorouracil None. J0401 ABILIFY MAINTENA aripiprazole i.v. J9264 ABRAXANE paclitaxel protein bound J3262 ACTEMRA IV tocilizumab Yes, through Navitus. Restricted to (in at least consultation
More information2017 MDwise HIP Medical Services that Require Prior Authorization
2017 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services Facility to facility ambulance
More informationJ1556 INJECTION, IMMUNE GLOBULIN (BIVIGAM) 500 MG $ J1559 INJECTION, IMMUNE GLOBULIN (HIZENTRA) 100 MG $14.364
G0333 INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.470 J0285 INJECTION, AMPHOTERICIN B 50 MG $10.280 J0287 INJECTION, AMPHOTERICIN B LIPID COMPLEX 10 MG $21.850 J0288
More informationQuarterly Pharmacy Formulary Change Notice
Quarterly Pharmacy Formulary Change Notice Summary of Change: The formulary changes listed in the table below were reviewed and approved at our December 18, 2014 Value Assessment Committee (VAC) meeting.
More information2018 MDwise HIP Medical Services that Require Prior Authorization
2018 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services Facility to facility ambulance
More informationDME MAC Jurisdiction C Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2018 through 03/31/2018
G0333 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.068 J0285 INJECTION, AMPHOTERICIN B 50 MG $32.987 J0287 INJECTION,
More informationDME MAC Jurisdiction B Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2019 through 03/31/2019
G0333 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.048 J0285 INJECTION, AMPHOTERICIN B 50 MG $31.668 J0287 INJECTION,
More information2018 MDwise HIP Medical Services that Require Prior Authorization
2018 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services Facility to facility ambulance
More informationCriteria for Medical Benefit Drugs Requiring Clinical Review
Note: Authorization of a service based on the clinical information provided does not guarantee payment. The claim must be properly submitted and the member must be eligible on the date of service for the
More informationCriteria for Medical Benefit Drugs Requiring Clinical Review
Note: Authorization of a service based on the clinical information provided does not guarantee payment. The claim must be properly submitted and the member must be eligible on the date of service for the
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More information2018 MDwise HIP Medical Services that Require Prior Authorization
2018 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services Facility to facility ambulance
More informationNew Billing Guidelines for Home Infusion, Enteral and Parenteral Therapies Home Infusion Fee Schedule Effective July 1, 2009
STAT Bulletin PO Box 80 Buffalo, New York 14240-0080 May 12, 2009 Volume 15:Issue 18 To: All Home Health Care and Home Infusion Therapy Providers Contracts Effected: All Lines of Business New Billing Guidelines
More informationSUPPLEMENTARY INFORMATION
Table S1 Therapeutic biologic product approvals, classes and innovation categories: 16 24 Approval year Trade name Active Ingredient(s) Drug class Innovation category Approval date 16 Intron-A Interferon
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 6 Last Review Date: March 16, 2018 Xeljanz Description Xeljanz, Xeljanz
More informationPRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION
Abstral fentanyl citrate oral tablet Controlled Dangerous substance Actemra tocilizumab Monoclonal antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate
More informationInjectable Drugs Requiring Pre-Service Approval
Abatacept Orencia J0129, 10 mg 1500 FL LCD- L29051 1) For patients with rheumatoid arthritis with failure, intolerance or contraindications to methotrexate. Limit dosing to 40 mg Q 2 weeks. 2) For patients
More informationHigh Risk Medications
Department Policy Code: D: MM-5705 Entity: Fairview Health Services Department: Home Infusion Manual: Policies & Procedures Category: Medication Management Subject: High Risk Medications Purpose: To provide
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationPercent Brand Name Generic Name Strength How Supplied NDC from AWP/SWP Adcetris. Amprya dalfampridine 10 mg 60 count bottle
Department of General Services Procurement Division Contract # 01-14- 65-57 Pharmaceutical Acquisitions Section Exhibit G-1 April 30, 2015 Walgreens Specialty Pharmacy LLC, Products Pricing Crescent Healthcare,
More informationSTAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business
STAT Bulletin November 28, 2011 Volume 17: Issue 34 To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat
More informationLIMITED DISTRIBUTION MEDICATIONS
ACTEMRA IV (USSC can dispense 162 mg PFS) ACTHAR HP ACTIMMUNE ADAGEN ADCETRIS CVS Specialty 1-800-237-2767 1-800-237-2767 ADEMPAS ADVATE ALDURAZYME ALECENSA ALIQOPA ALUNBRIG AMPYRA APOKYN ARALAST NP ARCALYST
More informationImmune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)
More informationUPMC for You Pharmacy and Therapeutics Committee Meeting July 27, 2010 meeting
1. Call to order: The meeting was called to order at 7:10 a.m. UPMC for You Pharmacy and Therapeutics Committee Meeting July 27, 2010 meeting 2. Review of the minutes: The minutes of the April 6, 2010
More informationUtilization Management
Abraxane Abraxane Actemra (IV) Inflammatory Conditions PA/Step Actemra (SQ) Inflammatory Conditions PA/Step Acthar HP Miscellaneous CNS Disorders PA Actimmune NF Adcetris Adcirca Adempas Advate (all forms)
More informationBrand Generic J-Code 1 Billable. Exclusion Criteria. Information and Criteria. Unit
Affinity Health Plan Department Of Pharmacy (Medicaid, Child Health Plus, Family Health Plus, Medicare Part B) **Medications Requiring Authorization under Medical Benefit** Click Here For Medication Authorization
More information2018 INJECTABLE DRUG PRIOR AUTHORIZATION CRITERIA
2018 INJECTABLE DRUG PRIOR AUTHORIZATION CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) These drugs require authorization before dispensing
More informationACTEMRA (tocilizumab)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced
More informationDrug Name Generic Name J-Code Unclassified Drugs in excess of $10,000
Unclassified Drugs in excess of $10,000 J3490 Unclassified Biologics in excess of $10,000 J3590 Revenue Codes in excess of $10,000 R250 - R259 ABRAXANE paclitaxel protein-bound J9264 & J9267 ACTEMRA tocilizumab
More informationActemra. Products Affected ACTEMRA INTRAVENOUS. Covered Uses
Actemra ACTEMRA INTRAVENOUS All medically accepted indications not otherwise excluded plus patients already started on tocilizumab for a covered use. Castleman's disease. Still's disease. Concurrent use
More informationDrug Use Evaluation: Physician Administered Drugs (PADs)
Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Drug Use Evaluation: Physician Administered
More informationEssential Health Benefits Standard Specialty PA and QL List July 2016
Anti-infectives Antiretrovirals, HIV SELZENTRY (maraviroc) Cardiology Antilipemic Pulmonary Arterial Hypertension Central Nervous System Anticonvulsants Depressant Neurotoxins Parkinson's Sleep Disorder
More informationHighmark List of Procedure Codes Requiring NDC Effective 12/01/2017
90378 RESPIRATORY SYNCYTIAL VIRUS, MONOCLONAL ANTIBODY, RECOMBINANT, FOR INTRAMUSCULAR USE, 50 MG, EACH C9399 Unclassified Drugs or biologicals J0129 INJECTION, ABATACEPT, 10 MG J0130 INJECTION ABCIXIMAB,
More informationContents Please refer to Medical Policy I-31, Tocilizumab (Actemra) for additional information.
In This Issue January 2018 Coverage Criteria Revised for Alpha1-Proteinase Inhibitor Infusions... 2 Coverage Criteria Revised for Eculizumab (Soliris)... 3 Coverage Criteria Revised for Chimeric Antigen
More informationMarch 2017 Pharmacy & Therapeutics Committee Decisions
UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed
More informationBilling for Infusion Services in an Outpatient Neurology Clinic. Christine Mann, MBA Director of Infusion Services Dent Neurologic Institute
Billing for Infusion Services in an Outpatient Neurology Clinic Christine Mann, MBA Director of Infusion Services Dent Neurologic Institute Overview of Infusion Billing Codes Current Procedure Terminology
More informationSELF-ADMINISTERED MEDICATIONS LIST
SELF-ADMINISTERED MEDICATIONS LIST Table of Contents Page Last Updated: January 23, 2019 INSTRUCTIONS FOR USE... 1 APPLICABLE CODES... 1 Related Commercial Policy LIST HISTORY/REVISION INFORMATION... 5
More informationMedi-Cal DHCS Carve Out Medication List
Medi-Cal DHCS Carve Out Medication List The drugs shown below are non-capitated or carved-out of Managed Care Plans (MCPs). IE H P i s a man ag ed c a r e p l a n. T his means they are not reimbursed by
More information2019 INJECTABLE DRUG PRIOR AUTHORIZATION CRITERIA
2019 INJECTABLE DRUG PRIOR AUTHORIZATION CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) These drugs require authorization before dispensing
More informationPharmacy Management Drug Policy
SUBJECT: POLICY NUMBER: PHARMACY-63 EFFECTIVE DATE: 12/04 LAST REVIEW DATE: 1/29/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara
More informationMDwise HIP Prior Authorization and Drug List
MDwise HIP Prior Authorization and Drug List Services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services With the exception of ER, Ambulance, Urgent Care Center
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)
More informationCosentyx. Cosentyx (secukinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx
More information1199SEIU Benefit Funds
1199SEIU Benefit Funds MEDICAL BENEFIT MANAGEMENT PROGRAM SPECIALTY DRUG LIST Effective January 1, 2019 As of April 1, 2015, providers must use the web-based ExpressPAth platform to obtain prior authorization
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationMedication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013
Medication Policy Manual Policy No: dru289 Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1,
More informationOtezla. Otezla (apremilast) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background
More informationMedication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014
Medication Policy Manual Policy No: dru342 Topic: Otezla, apremilast Date of Origin: May 9, 2014 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1, 2015 IMPORTANT
More information(Last Revised 10/04/18)
Department Of Pharmacy (Medicaid, Child Health Plus, Medicare Part B, Qualified Health Plan, Essentials Plan, Enriched Health () Medications Requiring Authorization under Medical Benefit Fax request to
More informationDrug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases
Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy
More informationTable III: 2019 Medicare Drug Fee Schedule* CY st Quarter Average Sales Price (ASP) Data Plus 6 Percent
Table III: 2019 Medicare Drug Fee Schedule* CY 2019 1st Quarter Average Sales Price (ASP) Data Plus 6 Percent *The Medicare payments allowance limits are effective Jan. 1 thru March. 31, 2019. CY 2019
More informationLDI integrated pharmacy services
8 ARRANON CARIMUNE NF Immunodeficiency 8-MOP Psoriasis ARZERRA CAYSTON Cystic Fibrosis A ASTAGRAF XL Antirejection CERDELGA Gaucher's Disease abacavir ATRIPLA CEREZYME Gaucher's Disease abacavir/lamivudine/
More informationMedical Prior Authorization List Rosen Employee Plans For prescription drug requirements, contact EHIM toll-free at
For prescription drug requirements, contact EHIM toll-free at 1.800.311.3446. General Information These requirements are administered by Health First Health Plans ( Health Plan ). Benefits are determined
More informationRHEUMATOID ARTHRITIS DRUGS
Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra
More informationPulmonary Hypertension Weight Loss Skin Conditions. Skin Conditions Multiple Sclerosis Endocrine Disorder. Endocrine Disorder.
Prior Authorization PricewaterhouseCoopers The following medications may require prior authorization prior to dispensing at a participating retail pharmacy or through the Express Scripts Pharmacy home
More informationDownload full Test Bank for Focus on Nursing Pharmacology 6th Edition by Karch
Download full Test Bank for Focus on Nursing Pharmacology 6th Edition by Karch https://digitalcontentmarket.org/download/test-bank-for-focus-on-nursingpharmacology-6th-edition-by-karch Chapter 17 1. A
More informationBiologics for Autoimmune Diseases
Biologics for Autoimmune Diseases Goal(s): Restrict use of biologics to OHP funded conditions and according to OHP guidelines for use. Promote use that is consistent with national clinical practice guidelines
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior
More information